Pharmaceutical Research and Manufacturers of America: Difference between revisions
m Dated {{Citation needed}} x 2{{Expand section}} x 2. (Build p609) |
→Leadership: add |
||
| Line 10: | Line 10: | ||
==Leadership== |
==Leadership== |
||
===Billy Tauzin=== |
|||
{{Main article|Billy Tauzin}} |
|||
Tauzin started as CEO in 2005<ref>Judy Sarasohn [http://www.washingtonpost.com/wp-dyn/articles/A3504-2004Dec15.html Special Interests: Tauzin to Head Drug Trade Group] ''The Washington Post'' December 16, 2004; Page A35.</ref> and continued until he stepped down in 2010.<ref>Julian Pecquet. "PhRMA picks new president" ''The Hill'' July 14, 2010. Vol. 17 Issue 81 page 22.</ref> |
|||
===Chris Viehbacher=== |
===Chris Viehbacher=== |
||
Revision as of 01:23, 30 April 2011
Pharmaceutical Research and Manufacturers of America (PhRMA), founded in 1958, is a trade group representing the pharmaceutical research and biotechnology companies in the United States. PhRMA's stated mission is advocacy for public policies that encourage the discovery of new medicines for patients by pharmaceutical and biotechnology research companies. PhRMA's current CEO is John J. Castellani.
Mission
On its website, PhRMA states its "mission is winning advocacy for public policies that encourage the discovery of life-saving and life-enhancing new medicines for patients by pharmaceutical / biotechnology research companies. To accomplish this mission, PhRMA is dedicated to achieving in Washington, D.C., the states and the world:[1]
- "Broad patient access to safe and effective medicines through a free market, without price controls,
- "Strong intellectual property incentives, and
- "Transparent, efficient, regulation and a free flow of information to patients."
Leadership
Billy Tauzin
Tauzin started as CEO in 2005[2] and continued until he stepped down in 2010.[3]
Chris Viehbacher
Chris Viehbacher is the Chairman of PhRMA's board of directors. Since 2008 Viehbacher has also served as CEO of Sanofi-Aventis. He was born on 26 March 1960. He holds both German and Canadian nationalities. Viebacher is a certified public accountant. He graduated from Queens University in Canada.[4]
John J. Castellani
John J. Castellani is President and CEO of PhRMA. Castellani has promised that PhRMA will continue to support healthcare reform efforts in the United States and abroad. Specifically, PhRMA will focus on helping to successfully implement and improve the health reform legislation passed in 2010 under President Obama with a particular emphasis on rewarding innovation.[5]Jeffrey Kindler, the chairman of Pfizer and former chairman of PhRMA, when commenting on Castellani's move from the Business Roundtable to PhRMA, said, “John is the gold standard, and I’m extremely pleased that he will lead our team."[6] Mr. Castellani succeeds Billy Tauzin, a former Republican congressman from Louisiana.[6]
Issues
Medicare part D
![[icon]](/wiki/File:Wiki_letter_w_cropped.svg){kind=small} | This section needs expansion. You can help by adding to it. (April 2011) |
Patient Protection and Affordable Care Act
| This section needs expansion. You can help by adding to it. (April 2011) |
Intellectual property
Every year, PhRMA makes substantial efforts with regard to Special 301 Report issued by the [[Office of the [United States Trade Representative]] on the enforcement of intellectual property laws abroad.[citation needed] PhRMA's recommendations for the Special 301 Report in 2009 were especially critical of the Philippines for "breaking patents" and failing to abide by the Agreement on Trade-Related Aspects of Intellectual Property Rights, commonly known as TRIPS.[7]
Doha
PhRMA has worked to minimize the effect of the November 2001 Doha Declaration by the Doha round of negotiations.[citation needed]
Members
Some prominent members of PhRMA include the following. A full list of members is available at the PhRMA website.[8]
- AstraZeneca
- Bayer
- Boehringer Ingelheim
- Bristol-Myers Squibb
- Eli Lilly and Company
- Genzyme Corporation
- GlaxoSmithKline
- Merck
- Novartis
- Pfizer
- Sanofi-Aventis
See also
- European Federation of Pharmaceutical Industries and Associations (EFPIA)
- Food and Drug Administration (FDA, USA)
- International Federation of Pharmaceutical Manufacturers Associations (IFPMA)
- International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH)
- Japan Pharmaceutical Manufacturers Association (JPMA)
- Pharmaceutical Inspection Convention and Pharmaceutical Inspection Co-operation Scheme
- SAFE-BioPharma Association (SAFE)
References
- ^ "Mission Statement". PhRMA. Retrieved 6 February 2011.
- ^ Judy Sarasohn Special Interests: Tauzin to Head Drug Trade Group The Washington Post December 16, 2004; Page A35.
- ^ Julian Pecquet. "PhRMA picks new president" The Hill July 14, 2010. Vol. 17 Issue 81 page 22.
- ^ "Chris Viehbacher Biography". Pharmaceutical Research and Manufacturers of America. Retrieved 6 April 2011.
- ^ whorunsgov.com
- ^ a b Pharmaceutical group shifts tone with new pick for president, by N.C. Alzenman and Dan Eggen, The Washington Post, 14 July 2010
- ^ Jessica Anne D. Hermosa (4 March 2009). "US lobby wants RP penalized for cheaper drugs law". BusinessWorld.
{{cite news}}:|access-date=requires|url=(help) - ^ [1]
External links